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valuable resource to support practitioners and clinics in 
addressing this important aspect of being human. 
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Purpose: A recently published practice-changing multicentre 
randomized study demonstrated no difference in overall survival 
(OS) and progression-free survival (PFS) between a short RT 
(arm1: 25 Gy in five fractions) and standard RT (arm 2: 40 Gy in 
15 fractions) in elderly and/or frail patients with glioblastoma 
multiforme (GBM). The purpose was to compare study arms for 
health-related quality of life (HR-QoL). 
Methods and Materials: EORTC core questionnaire QLQ-C30 and 
the brain module QLQ-BN20 were used to assess HR-QoL at 
baseline prior to RT, four weeks after RT completion and every 
three months thereafter until the disease progression. QoL 
scores over time were examined using generalized estimating 
equation adjusting for the treatment arms.  
Results: Of 98 randomized patients, 96 were eligible for QoL 
analysis. There was no difference in global QoL/main function 
scales/symptoms (except for insomnia) between arms. 
Improvement of global QoL, social and physical function, fatigue 
and insomnia were observed when comparing baseline to four 
months post-treatment, but only significant for insomnia, 
favouring arm 2. Difference of ≥ 10 points from baseline to four 
months was demonstrated for social function and insomnia (arm 
1), physical function (both arms) and fatigue (arm 2). Global QoL 
at baseline was significantly worse for arm 1, but statistically 
insignificant at one month and four months post-radiotherapy. 
Conclusions: There was overall no difference in HR-QoL between 
the two arms. A trend toward significant difference was seen in 
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Purpose: Cancer staging, which consists in objectifying the 
extent of cancer spread, is essential before the initiation of 
therapy. Staging is often incorrectly performed, with a sizeable 
portion of patients receiving unnecessary staging tests, which are 
costly. This study seeks to quantify the cost of such unnecessary 
tests in patients with early-stage breast cancer in the province 
of Québec, Canada. 
Methods and Materials: All patients diagnosed with breast 
cancer between 2012 and 2014 and listed in the tumour registry 
of the McGill University Health Centre, were included in this 
retrospective study. For each patient with early-stage breast 
cancer, the type and number of unnecessary staging tests, as per 
national guideline definitions, was extracted from the medical 
chart. The cost of each test, from a single payer point of view, 
was obtained from the Quebec government manuals of payment 
to physicians and departments. The total cost of unnecessary 
tests for staging of early-stage breast cancer was derived. 
Finally, an extrapolation was done to estimate the total cost for 
the whole province of Québec per year, given the number of 
diagnoses of breast cancer in that province. 
Results: 1845 patients were listed in the tumour registry of the 
MUHC, 1116 of which were diagnosed with early-stage breast 
cancer. 82.5% of patients underwent at least one inappropriate 
staging test, with an average of 2.35 inappropriate tests were 
performed per patient. Less than 1% of these tests detected 
metastatic disease. The average theoretical cost of 
inappropriate staging tests per patient was $235.84, $251.83 and 
$217.34 for 2012, 2013, and 2014 respectively, with an average 
total cost to the government of Québec of $830,659.61 per year, 
and a 10-year cost of $8,306,596.18. 
Conclusions: The majority of patients with early-stage breast 
cancer undergo unnecessary staging tests. In a social system with 




GLOBAL ACCESS TO RADIOTHERAPY FOR CERVICAL CANCER: THE 
COST OF INACTION  
Danielle Rodin1, Timothy P. Hanna2, Emily Burger3, Eduardo 
Zubizarreta4, Mei Ling Yap5, Michael Barton5, Rifat Atun3, Felicia 
Knaul6, Jacob Van Dyk7, Yolande Lievens8, Mary Gospodarowicz9, 
David Jaffray9, Michael Milosevic9 
1University of Toronto, Toronto, ON 
2Cancer Research Institute, Queen’s University, Kingston, ON 
3Harvard T.H. Chan School of Public Health, Boston, MA 
4International Atomic Energy Agency, Vienna, Austria 
5University of South Wales, Liverpool, Australia 
6University of Miami, Miami, FL 
7University of Western Ontario, London, ON 
8Ghent University Hospital, Ghent, Belgium 
9Princess Margaret Cancer Centre, Toronto, ON 
 
Purpose: Radiotherapy (RT) is a highly effective and curative 
treatment for patients with invasive cervical cancer, and is the 
standard of care for locally advanced disease. Although RT can 
be successfully delivered in developing countries, major gaps in 
access have resulted in substantial preventable morbidity and 
mortality, where nearly 90% of cervical cancer deaths occur. 
These gaps are multifactorial, but assumptions about excessive 
cost of RT in these regions preclude effective implementation. 
Using methodology developed for the Global Task Force on 
Radiotherapy for Cancer Control (GTFRCC), we examined the 
validity of these assumptions for the treatment of cervical 
cancer with external beam radiation (EBRT) and brachytherapy 
(BT) in upper middle-income income (UMIC), lower middle-
income (LMIC) and low-income countries (LIC). 
Methods and Materials: Based on the GTFRCC evidence-based 
estimation approach, we assumed that 71% of cervical cancer 
patients would require RT, with a mean of 21 EBRT and three 
HDR BT fractions per course, resulting in a 20% overall survival 
benefit. We developed a decision-analytic Markov model to 
assess three RT capacity scenarios from 2015 to 2035: 1) no 
increase in capacity; 2) linear scale-up from baseline coverage 
in 2015 to universal accessibility by 2035; and 3) immediate full 
availability. Model outcomes included total life years (LYs) and 
economic productivity (US Dollar). Costs, based on the GTFRCC 
efficiency model, and benefits were discounted by 3% annually 
over a lifetime horizon. 
Results: If no action is taken to shift current RT capacity to 
universal accessibility, we project a loss of up to 21.4 million (M) 
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LYs and $271.3 billion (B) due to cervical cancer alone over the 
next 20 years. Based on a realistic linear investment model, RT 
yields an additional 9.8M LYs (2.9M in LIC, 4.7M in LMIC, and 2.2M 
in UMIC) over 20 years, a $53.2B net increase in economic 
productivity ($2.6B in LIC, $16.4B in LMIC, and $34.2B in UMIC), 
and a broader societal net gain of $137.5B ($10.3B in LIC, $44.8B 
in LMIC, and $82.4B in UMIC). The additional investment 
necessary for HDR brachytherapy, an essential component of 
curative treatment, was only 5.5% greater than EBRT alone. 
Conclusions: The failure to ensure global availability of EBRT and 
BT to treat cervical cancer would result in enormous human and 
economic consequences over the next two decades. This loss 
would occur before the benefits of primary cancer prevention 
strategies, such as HPV vaccination, are realized. The present 
study demonstrates that a realistic investment strategy over the 
next 20 years may yield a net economic benefit of up to $150B 
USD, and potentially further benefits beyond that point in time. 
These findings support the value of scaling-up of EBRT and BT to 
treat cervical cancer and help to justify their inclusion in 
national cancer control planning. 
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Purpose: To compare emergency department (ED) use between 
patients with cancer and a matched cancer-free cohort of 
individuals and to examine the association between ED use and 
time to death. 
Methods and Materials: Data were from the Manitoba Centre for 
Health Policy Data Repository and included cancer registry, 
hospital discharge abstracts, physician billing claims, ED visits, 
and vital statistics. The cancer cohort included adults (age 18+) 
with selected cancer diagnoses (breast, colorectal, lung and 
prostate) made between 2007 and 2011. Rates of ED utilization 
were compared during three time periods (pre-, peri-, and post-
diagnosis) using generalized estimating equations between 
cancer patients and cancer-free individuals matched 1:1 on age, 
sex, and Charlson comorbidity score. The association between 
ED use and time to death was tested using a multivariable Cox 
proportional hazards regression model. 
Results: A total of 5569 patients with breast (n = 1555), 
colorectal (n = 1327), lung (n = 1437), and prostate (n = 1250) 
cancer were included. When comparing ED utilization between 
cancer cases by site and their matches only lung cancer showed 
a significant increase during the pre-diagnosis period (relative 
rate [RR] 1.38 [95% confidence interval 1.18-1.62], p < 0.0001). 
ED utilization was increased during the peri-diagnosis period for 
breast (RR 1.74 [1.31-2.32], p = 0.0001), colorectal (RR 2.44 
[1.72-3.45], p < 0.0001), lung (RR 4.51 [3.61-5.63], p < 0.0001), 
and prostate (RR 3.10 [2.14-4.47], p < 0.0001) cancer. In the 
post-diagnosis period, ED utilization was increased for breast (RR 
1.45 [1.26-1.67], p < 0.0001), colorectal (RR 1.40 [1.11-1.76, p = 
0.0005), and lung (RR 2.28 [1.94-2.67], p < 0.0001) cancer. ED 
use in the year prior to diagnosis was associated with time to 
death for prostate cancer (hazard ratio [HR] 1.12 [95% CI 1.02-
1.24], p < 0.02) while ED use in the post-diagnosis period was 
associated with time to death for breast (HR 1.27 [1.18-1.37], p 
< 0.0001), colorectal (HR 1.11 [1.04-1.18], p = 0.0012), and lung 
(HR 1.10 [1.06-1.14], p < 0.0001) cancer. 
Conclusions: The pattern of ED utilization varies with cancer site 
and time from diagnosis. All cancer sites were associated with 
increased ED use around the time of diagnosis, while patients 
with breast, colorectal, and lung cancers also showed increased 
ED use in the post-diagnosis period. Additional cancer-related 
urgent care services during the peri- and post-diagnosis periods 
may alleviate the frequency of ED visits among patients with 
cancer. 
13 
POST-OPERATIVE "MINIPELVIS" RADIOTHERAPY WITH OR WITHOUT 
VAGINAL VAULT BRACHYTHERAPY BOOST FOR STAGE II 
ENDOMETRIAL CANCER  
Kim Paulson, Natalie Logie, Fleur Huang, Robert Pearcey, 
Sunita Ghosh, Brad Murray, Geetha Menon, Ericka Wiebe
University of Alberta, Edmonton, AB  
Purpose: Patients with FIGO Stage II endometrial cancer (EC) are 
generally treated surgically, with risk-adapted adjuvant 
radiotherapy (external beam radiotherapy (EBRT) and/or vaginal 
vault brachytherapy (BT) boost) still suboptimally defined. With 
changing surgical practices in nodal assessment and/or 
resection, opportunity exists for selected patients to receive less 
intensive adjuvant therapy, with the goal of lessening treatment-
related morbidity. In this single-institutional review, we explore 
outcomes of Stage II EC patients treated with adjuvant 
“minipelvis” (MP)-EBRT (a field covering at least the surgical 
bed, vaginal vault, and parametria, but not the classical elective 
nodal regions) +/- BT. 
Methods: Women with pathologic Stage II EC receiving post-
operative MP-EBRT from 2000 onwards were reviewed. 
Demographics, disease characteristics, treatment details, 
survival, and recurrence data were collected. Three-year 
relapse-free survival (RFS) and overall survival (OS) were 
calculated from the date of surgery (Kaplan-Meier method). 
Median RFS and OS were compared between those receiving MP-
EBRT+BT and those receiving MP-EBRT alone (log rank test). 
Univariate analysis was performed (binary logistic regression) to 
determine factors associated with relapse. 
Results: n = 42 patients (median age 63 years [36-86]) received 
adjuvant MP-EBRT (2000-2015), with median follow up 27 months 
(2-105). n = 37 (88%) had pelvic lymph node dissection. 
Endometrioid adenocarcinoma was predominant (71%) over other 
histologies. n = 20 had Grade 3 disease, n = 18 had deep (> 50%) 
myometrial invasion (MI), and n = 22 had lymphovascular invasion 
(LVI). n = 10 received adjuvant chemotherapy. MP-EBRT fields 
had conventional inferior and lateral borders and height less than 
12 cm (range 7.8-11.8). Dose fractionation was typically 45 Gy in 
25 fractions (40-52.6 Gy/20-25), and 32 (76%) received 
subsequent HDR BT boost, typically 15 Gy in three fractions (15-
18 Gy/3) prescribed to vaginal surface. Ten patients relapsed 
(one vaginal recurrence, three in pelvis outside the field, six 
distant), four (40%) of those not receiving BT versus 19% of the 
BT group (OR 3.5, 95%CI 0.7-16.9, p = 0.125). Median time to 
relapse was 20 months (10-32). Tumour grade, LVI, and MI were 
not significantly associated with relapse. Three-year RFS and OS 
were 74% and 92% respectively. 
Conclusions: In this small series, early outcomes following 
adjuvant MP-EBRT for Stage II EC align with those reported for 
conventional adjuvant EBRT, suggesting that this is a reasonable 
approach. Only three patients relapsed in the pelvis outside of 
the field. Further characterization of tumour and toxicity 
outcomes can help to better define the population most likely to 
benefit from MP-EBRT, and the value of BT boost in this setting. 
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Purpose: To document the practice of brachytherapy (BT) and 
external beam radiotherapy (EBRT) for management of cervical 
cancer across Ontario, Canada with a population of 13.6 million. 
Methods and Materials: An electronic survey (SurveyMonkey) 
